药物重定向用于球细胞疾病:一个未充分利用的资源.
Monica Suet Ying Ng1,2,3,4, Gursimran Kaur5,6,7, Ross S Francis8,9
1Kidney Health Service, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia. monica.ng@health.qld.gov.au.
Nature reviews. Nephrology
|July 31, 2024
概括
药物重定向为球细胞疾病提供了新的无类固醇治疗方法,包括儿童和服务不足的人群的选择. 数据驱动和实验方法识别潜在的候选人,扩大治疗策略.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 药理学 药理学是指药理学的学科.
- 药物发现 药物发现 药物发现
背景情况:
- 淋巴细胞疾病与当前的治疗方法存在挑战,需要新的治疗方法.
- 类固醇依赖的治疗方案和对抗性病例的有限选择凸显了对替代策略的需求.
- 缺乏研究的人群和资源有限的环境需要可访问和有效的治疗解决方案.
研究的目的:
- 探索药物重定向治疗质细胞疾病的潜力.
- 识别现有的药物,可以重新用于球体疾病管理.
- 概述在该领域扩大药物重定向努力的策略.
主要方法:
- 使用疾病病理生物学,药物特征和临床结果进行数据驱动的识别.
- 通过高通量药物查进行实验性鉴定.
- 分析药物数据库,临床试验注册表和PubMed的潜在候选人.
主要成果:
- 至少有96种针对49种免疫抑制途径的已批准的药物是球细胞疾病重定位的潜在候选药物.
- 证据支持191种免疫药物向-球状腺疾病对进行重新定位.
- 非免疫学策略的目标是血液动力学过载,细胞损伤和纤维化.
结论:
- 药物重定向为球细胞疾病提供无类固醇,个性化和多目标治疗机会.
- 扩大药物重新用途需要丰富的数据库,可访问的临床数据,生物标志物发现和减少监管障碍.
- 这种方法可以增强不同患者群体和环境的治疗选择.
相关概念视频
Renal Corpuscle
1.8K
The glomerulus and Bowman's capsule are two essential components of the nephron, which is the functional unit of the kidney. These microscopic structures play a critical role in the process of blood filtration to produce urine.
Glomerulus: Structure and Function
The glomerulus is a tiny, intricate network of capillaries located at the beginning of the nephron. It's enveloped by the Bowman's capsule and receives its blood supply from an afferent arteriole, which divides into numerous...
Glomerulus: Structure and Function
The glomerulus is a tiny, intricate network of capillaries located at the beginning of the nephron. It's enveloped by the Bowman's capsule and receives its blood supply from an afferent arteriole, which divides into numerous...
1.8K
Renal Drug Excretion: Glomerular Filtration
224
The kidney serves as the primary organ responsible for eliminating drugs and their metabolites from the body. This process, known as renal elimination, starts with glomerular filtration and results in urine formation. Each kidney houses millions of functional units called nephrons, where urine production occurs. A nephron has two main components: a renal corpuscle and a renal tubule.
Drugs gain access to the kidney via the renal artery, which progressively branches off into afferent arterioles....
Drugs gain access to the kidney via the renal artery, which progressively branches off into afferent arterioles....
224
Drug Elimination by Renal Route: Tubular Secretion
2.3K
Once the process of glomerular filtration is completed, blood carrying unfiltered drug molecules traverses through efferent arterioles and makes its way into the peritubular capillaries in the proximal tubule. A variety of carriers play a pivotal role in actively secreting drugs from these peritubular capillaries into the tubular fluid. The organic anion transporter transfers acidic drugs, against an electrochemical gradient, from the peritubular capillaries into the renal tubule cells and...
2.3K
Drug Elimination by Renal Route: Glomerular Filtration
5.6K
The kidney serves as the primary organ responsible for eliminating drugs and their metabolites from the body. This process, known as renal elimination, starts with glomerular filtration and results in urine formation. Each kidney houses millions of functional units called nephrons, where urine production takes place. A nephron has two main components: a renal corpuscle and a renal tubule. Drugs gain access to the kidney via the renal artery, which progressively branches off into afferent...
5.6K
Renal Drug Excretion: Tubular Reabsorption
144
Tubular reabsorption, a process occurring post-glomerular filtration of drugs in the renal tubule, is a critical determinant of drug half-life. During the process of renal excretion, as the glomerular filtrate progresses to the distal convoluted tubule (DCT), drugs that are highly permeable, lipophilic, and nonionized undergo passive reabsorption from the tubular fluid into the surrounding peritubular capillaries. This reabsorption process restricts their elimination through the kidneys. This...
144
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
413
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
413


